Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial
By Adria Calatayud
Novartis said an experimental drug for neuromuscular disease myotonic dystrophy type 1 didn't meet the primary goal in a late-stage trial.
The drug, del-desiran, was one of the three therapies the Swiss pharmaceutical company added to its pipeline through its $12 billion acquisition of Avidity Biosciences, Novartis said Tuesday.
In the study, del-desiran didn't show a significant improvement compared with placebo on the primary objective, Novartis said. The trial measured how long it took patients with myotonic dystrophy type 1 to open their hand after gripping.
The company said the drug showed evidence of clinical activity for other objectives, and that safety data were generally consistent with previous studies.
Novartis said it is evaluating the full dataset and will discuss the most appropriate path forward for del-desiran with health authorities.
The company reiterated its guidance for annual sales growth of 5% to 6% over the 2025-30 period.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
September 08, 2026 01:35 ET (05:35 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States